

**Immunohistochemical expression of EGFR in  
triple-negative breast cancer and its correlation  
with clinicopathological characteristics of these  
tumors**

*Thesis submitted in partial fulfillment of the M.D. degree in pathology*

*By*

**Mohammed Mahmoud Abd-Ellah Ali**

*(M.B.B.Ch., M.Sc.)*

Under supervision of

**Prof. Dr. Ahmed Mohamed Yehia El Hennawy**

*Professor of Pathology,*

*Faculty of Medicine, Cairo University*

**Prof. Dr. Samia Mohamed Gabal**

*Professor of Pathology,*

*Faculty of Medicine, Cairo University*

**Prof. Dr. Mostafa Samy Salem**

*Assistant professor of Pathology,*

*Faculty of Medicine, Cairo University.*

**Faculty of Medicine**

**Cairo University**

**2012**

### ACKNOWLEDGMENT

I would like to express my deep gratitude to my dear **Professor, Dr Ahmed Mohamed Yehia El Hennawy** professor of pathology, Cairo University, for his kind guidance, sincere encouragement, stimulating suggestions, valuable contributions and his generous continuous indispensable efforts throughout the work.

I am also very grateful to **Professor, Dr Samia Mohamed Gabal** professor of pathology, Cairo University, for her devotion in achieving meticulous revision and clarifying various points that were valuable and helpful to me. Her observations have greatly assisted and encouraged me.

I would like to sincerely thank **Professor, Dr Mostafa Samy Salem** assistant professor of pathology, Cairo University, for his friendly attitude, great help, sincere corporation and strong effort to make best of this work. He constantly supported me with his kind and important remarks.

Many thanks to all my professors who contributed to this work whether with technical assistance, an advice, an idea or even a simple word of encouragement.

I also thank and dedicate this work to my loving family, specially speaking, to my dear parents and my dear wife, for their inestimable support.

## Abstract

**Background:**

Triple negative breast carcinomas (TNBCs) are a group of primary breast tumors with aggressive clinical behavior that have no targeted therapy at present. EGFR expression has recently come into focus as an index for molecular targeting therapy. Histologic sections that included variable subtypes and grades of TNBCs were studied by immunohistochemistry with EGFR, using a standard avidin–biotin–peroxidase system.

**Results:** Twenty two cases showed variable positive reactivity for EGFR (55% of total cases).

**Conclusions:** the level of EGFR expression was relatively high as most studies stated, and agreed with most studies about the statement that EGFR expression is associated with worse prognosis.

**Key Words:** Triple, negative, TNBC, EGFR.

# CONTENTS

	Page
INTRODUCTION.....	1
AIM OF WORK.....	3
REVIEW OF LITERATURE.....	4
Epidemiology and risk factors of breast cancer.....	4
❖ Classification Of Breast Cancer.....	6
Histopathological classification.....	8
Etiologic classification of primary breast cancer.....	8
Clinico-radiological classification of breast cancer.....	8
Molecular classification of Primary Breast Cancer.....	8
Correlation between the molecular and the histopathological classification of primary breast cancer.....	14
Correlation between the molecular and the aetiologic classification of primary breast cancer.....	15
❖ Triple Negative Carcinomas.....	16
Epidemiology and risk factors of triple negative cancers.....	17
Pathological and genetic features of triple negative breast cancers.....	18
❖ Basal Breast Carcinoma.....	24
❖ Medullary Carcinoma.....	32
❖ Metaplastic Carcinoma.....	35
❖ Prognosis of breast cancer.....	39
❖ Hormone receptors.....	41
❖ HER2-neu.....	42
❖ HER1 gene and targeted therapy.....	43
❖ Staging Of Breast Cancer.....	47
MATERIALS AND METHODS.....	50
RESULTS.....	54
DISCUSSION.....	91

SUMMARY.....	98
CONCLUSION AND RECOMMENDATIONS.....	100
REFERENCES.....	102

## **LIST OF GRAPHS AND CHARTS**

No.	Title	Page
Chart 1	<i>Age distribution in the selected cases.....</i>	55
Chart 2	<i>Histological subtypes in the selected cases.....</i>	56
Chart 3	<i>Intra duct component in the selected cases.....</i>	57
Chart 4	<i>Nodal status in the selected cases.....</i>	58
Chart 5	<i>Tumor necrosis in the selected cases.....</i>	59
Chart 6	<i>Marked lymphoplasmacytic reaction in the selected cases.....</i>	60
Chart 7	<i>Angio-invasion in the selected cases.....</i>	61
Chart 8	<i>Stages in the selected cases.....</i>	62
Chart 9	<i>Grades in the selected cases .....</i>	63
Chart 10	<i>EGFR score in the selected cases.....</i>	64
Graph 1	<i>EGFR score and age groups .....</i>	66
Graph 2	<i>EGFR score and histological subtypes .....</i>	68
Graph 3	<i>EGFR score and tumor size.....</i>	70
Graph 4	<i>EGFR score and grades.....</i>	72
Graph 5	<i>EGFR score and axillary lymph nodes status.....</i>	74
Graph 6	<i>EGFR score and intraductal component.....</i>	76
Graph 7	<i>EGFR score and tumoral necrosis.....</i>	78

**LIST OF TABLES**

No.	Title	Page
1	<i>Major molecular subtypes of breast cancer determined by gene expression profiling.</i>	10
2	<i>Use of immunohistochemistry as surrogate marker for the molecular subtypes of breast cancer.</i>	11
3	<i>Distribution of basal breast carcinoma percentage among the five breast cancer molecular subgroups in different studies.</i>	29
4	<i>Grading of the immunohistochemical staining of HER-2-neu overexpression regarding both the staining intensity as well as the percentage of stained tumor cells.</i>	43
5	<i>Age distribution in the selected cases.</i>	54
6	<i>Histological subtype in the selected cases.</i>	56
7	<i>Intra duct component in the selected cases.</i>	57
8	<i>Nodal status in the selected cases.</i>	58
9	<i>Tumor necrosis in the selected cases.</i>	59
10	<i>Marked lympho-plasmacytic reaction in the selected cases.</i>	60
11	<i>Angio-invasion in the selected cases.</i>	61
12	<i>Tumor size in the selected cases.</i>	62
13	<i>Grades in the selected cases.</i>	63
14	<i>EGFR scores in the selected cases.</i>	64
15	<i>EGFR score and age groups.</i>	65
16	<i>EGFR score and histological subtypes.</i>	67
17	<i>EGFR score and tumor size.</i>	69
18	<i>EGFR score and grades.</i>	71
19	<i>EGFR score and axillary lymph nodes status.</i>	73
20	<i>EGFR score and intraductal component.</i>	75
21	<i>EGFR score and tumoral necrosis.</i>	77
22	<i>EGFR score and marked lymphoplasmacytic reaction.</i>	79
23	<i>EGFR score and angio-invasion.</i>	80

**LIST OF FIGURES**

No.	Title	Page
Figure 1	<i>Overview of the EGF signaling pathway.</i>	44
Figure 2	<i>Invasive ductal carcinoma (NOS), GII (H&amp;E x 200).</i>	81
Figure 3	<i>Invasive ductal carcinoma (NOS), GII (H&amp;Ex200). lymphoplasmacytic reaction is noted.</i>	81
Figure 4	<i>Invasive ductal carcinoma (NOS), GIII (H&amp;Ex200).</i>	82
Figure 5	<i>Medullary carcinoma (NOS), GIII (H&amp;Ex200).</i>	82
Figure 6	<i>Invasive ductal carcinoma with medullary features GIII (H&amp;Ex200).</i>	83
Figure 7	<i>Invasive ductal carcinoma with medullary features and prominent cytoplasmic clarity, GIII (H&amp;Ex200).</i>	83
Figure 8	<i>Metaplastic carcinoma, GIII, (H&amp;Ex200).</i>	84
Figure 9	<i>Metaplastic carcinoma with prominent angio-invasion, (H&amp;Ex200).</i>	84
Figure 10	<i>Invasive ductal carcinoma with focal spindling, GIII (H&amp;Ex100).</i>	85
Figure 11	<i>Intra Duct Carcinoma, cribriform type, (H&amp;Ex200).</i>	85
Figure 12	<i>Invasive ductal carcinoma with geographic necrosis, GIII, (H&amp;Ex200).</i>	86
Figure 13	<i>EGFR Immuno-Stained Control Slide Of Squamous Cell Carcinoma -Score 3- (x200).</i>	86



## *List of figures*

Figure 14	<i>EGFR Immunostaining For Invasive Duct Carcinoma -Score 3- (x400).</i>	87
Figure 15	<i>EGFR Immunostaining For Invasive Duct Carcinoma - Score 3- (x400).</i>	87
Figure 16	<i>EGFR Immunostaining For Invasive Duct Carcinoma -Score 3- (x400).</i>	88
Figure 17	<i>EGFR Immunostaining For Invasive Duct Carcinoma -Score 3- (x400).</i>	88
Figure 18	<i>EGFR Immunostaining For Medullary Carcinoma -Score 3- (x400)</i>	89
Figure 19	<i>EGFR Immunostaining For Metaplastic Carcinoma -Score 1- (x400)</i>	89
Figure 20	<i>EGFR Immunostaining For Invasive Duct Carcinoma -Score 2- (x400).</i>	90
Figure 21	<i>EGFR Immunostaining For Intra Duct Carcinoma -Score 3- (x200).</i>	90

### **LIST OF ABBREVIATIONS**

- **BLBC:** Basal-like Breast Cancer.
- **BPBC:** Basal Phenotype Breast Cancer.
- **BRCA-1:** Breast Cancer 1.
- **BRCA-2:** Breast Cancer 2.
- **CK5/6:** Cytokeratin 5/6.
- **CSCs:** Cancer Stem Cells.
- **DCIS:** Ductal Carcinoma In Situ.
- **ECD:** Extracellular Domain.
- **EMT:** Epithelial to Mesenchymal Transition.
- **EGFR:** Epidermal Growth Factor Receptor.
- **ER:** Estrogen Receptor.
- **FDG-PET:** Fluorodeoxyglucose- Positron Emission Tomography.
- **FISH:** Fluorescent In Situ Hybridization.
- **GMP:** Glomeruloid Microvascular Proliferation.
- **HER-2/neu:** Human EGFR Related -2/neural.
- **HR:** Hormone Receptor.
- **IHC:** Immunohistochemistry.
- **MBCs:** Medullary Breast Carcinomas.
- **NR:** Nuclear Receptor.
- **NSCLC:** Non-Small Cell Lung Cancer.
- **OS:** Overall Survival.
- **PARP:** Poly(adenosine diphosphate-ribose) Polymerase.
- **pCR:** pathologic Complete Response.
- **PFS:** Progression- Free Survival.
- **PMRT:** Post-Mastectomy Radiation Therapy.
- **PR:** Progesterone Receptor.
- **TDLU:** Terminal Duct Lobular Unit.
- **TKIs:** Tyrosine Kinase Inhibitors.

## INTRODUCTION

Breast cancer is the most common female cancer, worldwide, more than a million women are diagnosed every year, however despite this increase, the mortality rate is declining, this is due to combination of factors including early diagnosis and effective treatment (*Keshtgar et al., 2010*).

In the national cancer institute of Egypt, in the period between 2003 and 2004, breast cancer came as number one in ranking of malignant tumors constituting 17.50% of total malignancies (*Mokhtar et al., 2007*).

Breast cancer is a common but very diverse disease with considerable survival heterogeneity. An ongoing challenge is to find improved methods of identifying and classifying groups of tumors with differing biological behaviours or responsiveness to specific therapies (*Tavassoli et al., 2003*).

Triple negative breast carcinomas (TNBCs) are a group of primary breast tumors with aggressive clinical behavior. Most TNBCs possess a basal phenotype (BP). The importance of recognizing these tumors came to light largely as the result of gene expression profiling studies that categorized breast cancer into 3 major groups. Two of these groups are defined by their respective expression of estrogen receptor and HER2. TNBCs represent a third group and are defined by negativity for hormone receptors and HER2 (*Diaz et al., 2007*).

Epidermal growth factor receptor (EGFR) is a member of the ErbB family, a family of tyrosine kinase receptors with growth-promoting effects (*Rogers et al., 2005*).

EGFR expression in breast cancer has been investigated in a variety of studies whose results suggest that a relation to aggressive tumor behavior remains controversial, but that expression might be an indicator of less favorable response to anticancer agents, on the other hand, EGFR expression has recently

come into focus as an index for molecular targeting therapy; thus knowledge of a patient's immunohistochemical EGFR expression might be useful information to treat triple-negative breast cancer (*Tadahiro et al., 2010*).

### **AIM OF WORK**

- Histopathological studying of triple-negative breast carcinomas.
- To evaluate immunohistochemically the expression of EGFR in triple-negative female breast cancer and its relation to available clinicopathologic features.

**EPIDEMIOLOGY AND RISK FACTORS OF BREAST CANCER:**

Breast cancer ranks first among cancers affecting women throughout the world. Estimates suggest that more than 1,050,000 new breast cancer cases are added worldwide annually, with nearly 580,000 cases occurring in developed countries and the remainder in the developing countries (*Stewart et al., 2003*). Breast cancer accounts for 23% of cancer cases, it is estimated that approximately 1 in 11 women will suffer from the disease at some point in their lifetime, there were over 200,000 cases diagnosed in the U.S. alone in 2005, and the incidence of new cases continues to rise worldwide (*Parkin et al., 2005*). Triple negative breast carcinoma (TNBC) represents 10-17 % of all breast cancers (*Katerina et al., 2009*).

In Egypt, *Abd El-Bar et al., (2007)*, recorded that breast cancer was the most frequent cancer among Egyptian females, accounting for 17.5% of all incident cancers and 35.7% of all newly diagnosed female cancers over a period of three years (2000-2002).

Race is regarded as a prognostic factor in a sense that non-Hispanic black women with late-stage triple-negative breast cancer has the poorest survival of any comparable group, with a 5-year relative survival of only 14%, and this is much lower than other race groups with the same tumour; the 5-year relative survival is 36% for non-Hispanic white women and 37% for Hispanic women with late-stage triple-negative breast cancer. It is also much lower than the same race group, non-Hispanic black women, diagnosed at late stage with other breast cancers, for which the 5-year relative survival is 49% (*Tischkowitz et al., 2007*).

Although many epidemiological risk factors have been identified, the cause of any individual breast cancer is often unknowable. No etiology is known for

95% of breast cancer cases, while approximately 5% of new breast cancers are attributable to hereditary syndromes (*Giordano et al., 2004*).

Worldwide, breast cancer is the fifth most common cause of cancer death (after lung cancer, stomach cancer, liver cancer, and colon cancer). In 2005, breast cancer caused 502,000 deaths (7% of cancer deaths; almost 1% of all deaths) worldwide. Among women worldwide, breast cancer is the most common cause of cancer death (*Espey et al. 2007*).

The number of cases worldwide has significantly increased since the 1970s, a phenomenon partly blamed on modern lifestyles in the Western world. Because the breast is composed of identical tissues in males and females, breast cancer also occurs in males, though it is less common (*Espey et al. 2007*).

### **Risk Factors:**

#### **1- Atypia or cancer on previous biopsy:**

- Atypical ductal hyperplasia (ADH).
- Atypical lobular hyperplasia (ALH).
- Lobular carcinoma in situ (LCIS).
- Previous history of ductal carcinoma in situ (DCIS).
- Previous history of invasive breast cancer. (*Chen et al., 2002*).

#### **2- Thoracic Radiation Before Age 30:**

- e.g., Hodgkin's.
- Infant thymus radiation.
- Frequent fluoroscopy for TB.
- Multiple x-rays for scoliosis. (*Goss et al., 1998*).

#### **3- Family History—Three Generations Maternal and Paternal:**

- Known or suspected gene mutation
- Early age onset <40